![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Initiates Phase 2 Clinical Study of MM-111 in Advanced Gastroesophageal Cancers
July 22, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 22, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the enrollment of its first patient in a Phase 2 clinical trial of its bispecific...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Closes Concurrent Sale of 5,750,000 Shares of Common Stock and $125,000,000 Aggregate Principal Amount of Convertible Senior Notes
July 17, 2013 16:15 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 17, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the closing of its sale of 5,750,000 shares of its common stock at a price to the...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Prices Concurrent Public Offerings of 5,000,000 Shares of Common Stock and $125,000,000 Aggregate Principal Amount of Convertible Senior Notes
July 11, 2013 23:52 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 11, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it has priced concurrent public offerings of 5,000,000 shares of its common stock...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes
July 10, 2013 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 10, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced its intention to offer, subject to market and other conditions, $50 million of its...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
June 06, 2013 12:07 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 6, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that William Sullivan, CFO, is scheduled to present at the Goldman Sachs 34th Annual...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential for Investigation as Combination With Chemotherapy in Patients With Advanced Solid Tumors
June 04, 2013 09:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 4, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer
May 23, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2 randomized, double blind clinical...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Reports First Quarter 2013 Financial Results
May 13, 2013 10:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack to Present at Multiple Investor Conferences This Spring
May 02, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that their management team is scheduled to present at multiple investor conferences this...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Timing of First Quarter 2013 Investor Conference Call
April 30, 2013 10:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its First Quarter 2013 Investor Conference Call and...